Association for CANCER IMMUNOTHERAPY (CIMT)

1

29. DEUTSCHER KREBSKONGRESSBerlin 24. – 27. Februar 2010

Individualisierte Immunintervention in der Tumormedizin

www.cimt.eu

H.-G. Rammensee

C.Huber

G.Schuler

P. Johnson

C.Melief

U.Kalinke

P. Walden

Executive Board

CIMT – The People

Scientific Secretaries Local Organizers

C. Britten

S.Kreiter

T. Seppman

M. Diken

2

Scientific Advisory Board

P. Beckhove P. Bossart U. Keilholz

C. Ottensmeier G. Parmiani U. Sahin

M. Schmitt J. Schultze H. Singh

F. Stevenson T. Tüting T. Wölfel

3

CIMT – The Goals

To enhance development of cancer immunotherapy by:

1. Facilitating cooperation between academia, biotech, pharma and __regulatory agencies in the field of Scientific and Technical Research

o Scientific conferences, Working parties, Proficiency Panel Program

2. Education of health professionals and patients self-help __organizations

o Advanced education conferences & textbookso Patient Academy Cancer Immunotherapy

3. Cooperation with partners

o Consortia, Universities, Regulatory agencies, Scientific Journals, Foundations and Companies

o Patients advocacy groups

CIMT – The Organigramm

4

Executive Board

Scientific advisory Board

Scientific Secretaries

Communications Director

Annual MetingRegulatory Research

Group

CIMT Immunoguiding

Program

Patient Academy

Local Organizers

Adminstration

Annual Meetings

CIMT – The Annual Meetings

5

• Basic and translational tumor immunology

• >350 participants from academia, companies and regulatory authorities

• From >15 countries• > 100 abstracts• Working parties CIP & RRP• Industry workshops

CIMT – Annual Meeting 2009

6

Regulatory Research Group

Chair: U. Kalinke

Members: H. Singh, U. Sahin, J. Müller-Berghaus, T. Hinz, K.J. Kallen, C. Britten, S. Kreiter

7

CIMT – Regulatory Research Group

CVC Delegate

A. Hoos

Scientific Sessions

Comments to Guidelines

Co-operationsResearch Projects

EMEA Comments and suggestions regarding the planned implementation of the “Advanced

Therapy Medicinal Prodcuts „Regulation (EC) No 1394/2007 (7th July 2008)

FDA Draft Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines (16th Dec. 2009)

C. Gouttefangeas

C. Britten

S. Van der Burg

(Current Chair)

C. Ottensmeier

M. Welters

M. Kalos

8

CIMT – Immunoguiding Program (CIP)

Workshops + Scientific Sessions

Co-operation with other groups

Proficiency Panel Program

Dissemination of Datav

Services

HLA-peptideMultimers

ELISPOT Intracellular Cytokine Staining

25 participating labs (36 labs on the waiting list) 8 (11) European countries Mainz, Leiden, Tübingen (main organizers) Southampton, Copenhagen, Berlin (co-organizers)

CIP – Proficiency Panel Programm

Immune response Tumor size Patient survival

timeTreatment

early late

10

CIMT – Immunoguding Program (CIP)

T cell Immunomonitoring Imaging Techniques Clinical Endpoints

Announced in Immunity: www.miataproject.org

11

CIP – Minimal Information About T cell Assays

First consensus workshop will take place in Washington on

March 19th. Workshop is hosted by CRI-CVC and CIP.

Stem celltransplantation

2007 2010

12

CIMT – Educational Aspects

Education of health professionals & patients

o Advanced education meetings in collaboration with ESO-Do Patients Cancer Immunotherapy Academyo Text books

13

CIMT – Partners and Sponsors

Visit CIMT !

1414

CIMT – Safe The Date ! (May 26th-28th, 2010)

CIMT Homepage

o www.cimt.eu

CIMT on Twitter

o http://twitter.com/C_IMT

CIMT on facebook

o www.facebook.com/pages/CIMT-Association-for-Cancer-Immunotherapy/310545294710